Literature DB >> 17485601

Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats.

Frederic Pinaud1, Arnaud Bocquet, Odile Dumont, Kevin Retailleau, Christophe Baufreton, Ramaroson Andriantsitohaina, Laurent Loufrani, Daniel Henrion.   

Abstract

The role of angiotensin II type 2 receptors (AT2Rs) remains a matter of controversy. Its vasodilatory and antitrophic properties are well accepted. Nevertheless, in hypertensive rats, AT2R stimulation induces a vasoconstriction counteracting flow-mediated dilation (FMD). This contraction is reversed by hydralazine. Because FMD is also decreased in aging, another risk factor for cardiovascular diseases, we hypothesized that AT2R function might be altered in old-rat resistance arteries. Mesenteric resistance arteries (250 mum in diameter) were isolated from old (24 months) and control (4 months) rats receiving hydralazine (16 mg/kg per day; 2 weeks) or water. FMD, NO-mediated dilation, and endothelial NO synthase expression were lower in old versus control rats. AT2R blockade improved FMD in old rats, suggesting that AT2R stimulation produced vasoconstriction. AT2R expression was higher in old rats and mainly located in the smooth muscle layer. In old rats, AT2R stimulation induced endothelium-independent contraction, which was suppressed by the antioxidant Tempol. Reactive oxygen species level was higher in old-rat arteries than in controls. Hydralazine improved FMD and NO-dependent dilation in old rats without change in AT2R expression and location. In old rats treated with hydralazine, reactive oxygen species level was reduced in endothelial and smooth muscle cells, and AT2R-dependent contraction was abolished. Thus, AT2R stimulation induced vasoconstriction through activation of reactive oxygen species production, contributing to decrease FMD in old-rat resistance arteries. Hydralazine suppressed AT2R-dependent reactive oxygen species production and AT2R-dependent contraction, improving FMD. Importantly, endothelial alterations in aging were reversible. These findings are important to consider in the choice of vasoactive drugs in aging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485601      PMCID: PMC2231526          DOI: 10.1161/HYPERTENSIONAHA.106.085035

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  37 in total

Review 1.  Vascular endothelial dysfunction in aging: loss of Akt-dependent endothelial nitric oxide synthase phosphorylation and partial restoration by (R)-alpha-lipoic acid.

Authors:  A R Smith; T M Hagen
Journal:  Biochem Soc Trans       Date:  2003-12       Impact factor: 5.407

Review 2.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

3.  Effect of losartan in aging-related endothelial impairment.

Authors:  Sanjay Rajagopalan; Robert Brook; Rajendra H Mehta; Mark Supiano; Bertram Pitt
Journal:  Am J Cardiol       Date:  2002-03-01       Impact factor: 2.778

Review 4.  Free radicals in the physiological control of cell function.

Authors:  Wulf Dröge
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

5.  Decreased arteriolar sensitivity to shear stress in adult rats is reversed by chronic exercise activity.

Authors:  Dong Sun; An Huang; Akos Koller; Gabor Kaley
Journal:  Microcirculation       Date:  2002-04       Impact factor: 2.628

6.  Vascular and metabolic response to isolated small muscle mass exercise: effect of age.

Authors:  L Lawrenson; J G Poole; J Kim; C Brown; P Patel; R S Richardson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-08       Impact factor: 4.733

7.  Chronic hydralazine improves flow (shear stress)-induced endothelium-dependent dilation in mouse mesenteric resistance arteries in vitro.

Authors:  Diane Gorny; Laurent Loufrani; Nathalie Kubis; Bernard I Lévy; Daniel Henrion
Journal:  Microvasc Res       Date:  2002-07       Impact factor: 3.514

8.  Selected Contribution: Aging impairs nitric oxide and prostacyclin mediation of endothelium-dependent dilation in soleus feed arteries.

Authors:  Christopher R Woodman; Elmer M Price; M Harold Laughlin
Journal:  J Appl Physiol (1985)       Date:  2003-08-01

9.  AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade.

Authors:  Robert E Widdop; Khalid Matrougui; Bernard I Levy; Daniel Henrion
Journal:  Hypertension       Date:  2002-10       Impact factor: 10.190

10.  Superoxide-NO interaction decreases flow- and agonist-induced dilations of coronary arterioles in Type 2 diabetes mellitus.

Authors:  Zsolt Bagi; Akos Koller; Gabor Kaley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06-12       Impact factor: 4.733

View more
  15 in total

Review 1.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations.

Authors:  D H J Thijssen; G A Rongen; P Smits; M T E Hopman
Journal:  J Physiol       Date:  2007-10-25       Impact factor: 5.182

Review 4.  AT2 receptor activities and pathophysiological implications.

Authors:  Luis C Matavelli; Helmy M Siragy
Journal:  J Cardiovasc Pharmacol       Date:  2015-03       Impact factor: 3.105

Review 5.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

6.  Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

Authors:  A Koïtka; Z Cao; P Koh; A M D Watson; K C Sourris; L Loufrani; A Soro-Paavonen; T Walther; K J Woollard; K A M Jandeleit-Dahm; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

7.  Effects of aging, TNF-α, and exercise training on angiotensin II-induced vasoconstriction of rat skeletal muscle arterioles.

Authors:  Yoonjung Park; Rhonda D Prisby; Brad J Behnke; James M Dominguez; Lisa A Lesniewski; Anthony J Donato; Judy Muller-Delp; Michael D Delp
Journal:  J Appl Physiol (1985)       Date:  2012-08-23

Review 8.  Chemistry and antihypertensive effects of tempol and other nitroxides.

Authors:  Christopher S Wilcox; Adam Pearlman
Journal:  Pharmacol Rev       Date:  2008-12       Impact factor: 25.468

9.  Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats.

Authors:  S Bosnyak; R E Widdop; K M Denton; E S Jones
Journal:  Int J Hypertens       Date:  2011-11-30       Impact factor: 2.420

10.  COX-2-derived prostanoids and oxidative stress additionally reduce endothelium-mediated relaxation in old type 2 diabetic rats.

Authors:  Emilie Vessières; Anne-Laure Guihot; Bertrand Toutain; Maud Maquigneau; Céline Fassot; Laurent Loufrani; Daniel Henrion
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.